zinc-finger
(2)
Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a clinical-stage genomic medicine company in Brisbane, California that engineers zinc finger proteins to switch genes on, off, or rewrite them. After three decades pioneering zinc finger technology, it is racing to bring its lead gene therapy ST-920 for Fabry disease to market while building a neurology pipeline aimed at crossing the blood-brain barrier - all under the pressure of a 2026 search for strategic alternatives.
Sandy Macrae
Sandy Macrae is a Scottish physician-scientist who has led Sangamo Therapeutics, the Brisbane, California gene-editing pioneer, as President and CEO since June 2016. Trained at Glasgow and Cambridge - where Nobel laureate Sydney Brenner supervised his PhD - he ran emerging-markets R&D at GSK and was Global Medical Officer at Takeda before staking his career on zinc finger technology and genomic medicines for rare and neurological diseases.